Cargando…

Effects on health-related quality of life in patients treated with lurasidone for bipolar depression: results from two placebo controlled bipolar depression trials

BACKGROUND: Depressive symptoms associated with bipolar disorder negatively impact health-related quality of life (HRQoL). The efficacy of lurasidone in reducing depressive symptoms has been previously demonstrated. The objective of this study was to examine the direct and indirect effect (mediated...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rajagopalan, Krithika, Bacci, Elizabeth Dansie, Ng-Mak, Daisy, Wyrwich, Kathy, Pikalov, Andrei, Loebel, Antony
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4877991/ https://www.ncbi.nlm.nih.gov/pubmed/27215976 http://dx.doi.org/10.1186/s12888-016-0865-y

Ejemplares similares

The direct and indirect effects of lurasidone monotherapy on functional improvement among patients with bipolar depression: results from a randomized placebo-controlled trial
por: Rajagopalan, Krithika, et al.
Publicado: (2016)

PS37. Lurasidone in the Treatment of Bipolar Depression: Effect of Baseline Depression Severity on Clinical Outcome
por: Pikalov, Andrei, et al.
Publicado: (2016)

Sleep Disturbance, Irritability, and Response to Lurasidone Treatment in Children and Adolescents with Bipolar Depression
por: Singh, Manpreet K., et al.
Publicado: (2023)

Long-term health-related quality of life improvements among patients treated with lurasidone: results from the open-label extension of a switch trial in schizophrenia
por: Awad, George, et al.
Publicado: (2016)

Lurasidone in Children and Adolescents with Bipolar Depression Presenting with Mixed (Subsyndromal Hypomanic) Features: Post Hoc Analysis of a Randomized Placebo-Controlled Trial
por: Singh, Manpreet K., et al.
Publicado: (2020)

Lurasidone: a novel antipsychotic agent for the treatment of schizophrenia and bipolar depression
por: Loebel, Antony, et al.
Publicado: (2015)

Health-related quality of life among patients treated with lurasidone: results from a switch trial in patients with schizophrenia
por: Awad, George, et al.
Publicado: (2014)

Long-term use of lurasidone in patients with bipolar disorder: safety and effectiveness over 2 years of treatment
por: Pikalov, Andrei, et al.
Publicado: (2017)

Lurasidone for the treatment of depressive symptoms in schizophrenia: analysis of 4 pooled, 6-week, placebo-controlled studies
por: Nasrallah, Henry A., et al.
Publicado: (2014)

Hospitalization outcomes in patients with schizophrenia after switching to lurasidone or quetiapine: a US claims database analysis
por: Newcomer, John W., et al.
Publicado: (2018)

Tolerability, Safety, and Effectiveness of Two Years of Treatment with Lurasidone in Children and Adolescents with Bipolar Depression
por: DelBello, Melissa P., et al.
Publicado: (2021)

Weight changes before and after lurasidone treatment: a real-world analysis using electronic health records
por: Meyer, Jonathan M., et al.
Publicado: (2017)

Cardiometabolic comorbidities, readmission, and costs in schizophrenia and bipolar disorder: a real-world analysis
por: Correll, Christoph U., et al.
Publicado: (2017)

Lurasidone for Treating Schizophrenia and Bipolar Depression: A Review of Its Efficacy
por: Tarzian, Martin, et al.
Publicado: (2023)

Lurasidone for the treatment of bipolar depression: an evidence-based review
por: Franklin, Rachel, et al.
Publicado: (2015)

Management of bipolar I depression: clinical utility of lurasidone
por: Findlay, Lillian Jan, et al.
Publicado: (2015)

Double‐blind, placebo‐controlled study of lurasidone monotherapy for the treatment of bipolar I depression
por: Kato, Tadafumi, et al.
Publicado: (2020)

A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophrenia
por: Tandon, Rajiv, et al.
Publicado: (2016)

Lurasidone in the Treatment of Bipolar Depression: Systematic Review of Systematic Reviews
por: Fornaro, Michele, et al.
Publicado: (2017)

F60. INFLAMMATORY MARKERS AND COGNITIVE PERFORMANCE IN PATIENTS WITH SCHIZOPHRENIA TREATED WITH LURASIDONE
por: Pikalov, Andrei, et al.
Publicado: (2018)

Patient preferences for important attributes of bipolar depression treatments: a discrete choice experiment
por: Ng-Mak, Daisy, et al.
Publicado: (2017)

Cost-Utility Analysis of Lurasidone Versus Aripiprazole in Adults with Schizophrenia
por: Rajagopalan, Krithika, et al.
Publicado: (2016)

Daytime sleepiness associated with lurasidone and quetiapine XR: results from a randomized double-blind, placebo-controlled trial in patients with schizophrenia
por: Loebel, Antony D., et al.
Publicado: (2013)

Weight change during long-term treatment with lurasidone: pooled analysis of studies in patients with schizophrenia
por: Meyer, Jonathan M., et al.
Publicado: (2015)

T5. LURASIDONE AND RISK FOR METABOLIC SYNDROME IN PATIENTS WITH SCHIZOPHRENIA: A COMPREHENSIVE DATABASE ANALYSIS
por: Tocco, Michael, et al.
Publicado: (2018)

LURASIDONE IN THE LONG‐TERM TREATMENT OF PATIENTS WITH BIPOLAR DISORDER: A 24‐WEEK OPEN‐LABEL EXTENSION STUDY
por: Ketter, Terence A., et al.
Publicado: (2016)

Lurasidone compared to other atypical antipsychotic monotherapies for adolescent schizophrenia: a systematic literature review and network meta-analysis
por: Arango, Celso, et al.
Publicado: (2019)

PM413. Metabolic Syndrome in Patients With Schizophrenia Receiving Long-Term Treatment With Lurasidone, Quetiapine XR, or Risperidone
por: Newcomer, John W., et al.
Publicado: (2016)

F52. EFFICACY AND SAFETY OF LURASIDONE IN ADOLESCENTS WITH SCHIZOPHRENIA: INTERIM ANALYSIS OF A 24-MONTH, OPEN-LABEL EXTENSION STUDY
por: Goldman, Robert, et al.
Publicado: (2018)

Lurasidone as a potential therapy for bipolar disorder
por: Woo, Young Sup, et al.
Publicado: (2013)

Switching to Lurasidone following 12 months of treatment with Risperidone: results of a 6-month, open-label study
por: Mattingly, Greg W., et al.
Publicado: (2020)

Lurasidone versus Quetiapine for Cognitive Impairments in Young Patients with Bipolar Depression: A Randomized, Controlled Study
por: Diao, Xiangyuan, et al.
Publicado: (2022)

A diagnostic test to examine early improvement as a predictor of later response to lurasidone in bipolar depression
por: Kishi, Taro, et al.
Publicado: (2023)

TULIP study: Trail of Lurasidone in bipolar disorder in Pakistan()
por: Khan, Nasar, et al.
Publicado: (2021)

Long-term cost-effectiveness of atypical antipsychotics in the treatment of adults with schizophrenia in the US
por: O’Day, Ken, et al.
Publicado: (2013)

Relationship of Brain Glutamate Response to D-Cycloserine and Lurasidone to Antidepressant Response in Bipolar Depression: A Pilot Study
por: Dong, Zhengchao, et al.
Publicado: (2021)

Short-term efficacy and safety of lurasidone versus placebo in antipsychotic-naïve versus previously treated adolescents with an acute exacerbation of schizophrenia
por: Correll, Christoph U., et al.
Publicado: (2022)

Neurocognition Function of Patients With Bipolar Depression, Unipolar Depression, and Depression With Bipolarity
por: Lu, Zhe, et al.
Publicado: (2021)

Efficacy and Safety of Lurasidone in Adolescents with Schizophrenia: A 6-Week, Randomized Placebo-Controlled Study
por: Goldman, Robert, et al.
Publicado: (2017)

The Bipolar II Depression Questionnaire: A Self-Report Tool for Detecting Bipolar II Depression
por: Leung, Chi Ming, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_82gpemeim1bflnuekqoratrdk2